Profile data is unavailable for this security.
About the company
ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company is focused on developing peptide bio-drugs in specialty therapeutic areas. Its portfolio includes peptide therapeutics for autoimmune diseases and anti-infectives. Its lead program, P140 (Lupuzor), is an autophagy immunomodulator for the treatment of lupus. Its pipeline is focused on two therapeutic areas: autoimmunity/inflammation and anti-infectives. Its pipeline products in autoimmunity and inflammation therapeutic area includes Lupuzor and P140 for CIDP. Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB, a peptide-based drug that offers a potential improvement on the limiting side effects and poor administration regime of Amphotericin-B (AMB) formulations. BioCin, a peptide-based drug based on an existing antibacterial used in high medical need and in many cases as the last line of defense.
- Revenue in GBP (TTM)-69.96k
- Net income in GBP-2.46m
- Incorporated2000
- Employees5.00
- LocationImmuPharma PLCOne Bartholomew CloseLONDON EC1A 7BLUnited KingdomGBR
- Phone+44 207 152 4080
- Fax+44 207 152 4001
- Websitehttps://www.immupharma.co.uk/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ovoca Bio PLC | 0.00 | -3.30m | 1.59m | 5.00 | -- | 0.8548 | -- | -- | -0.0389 | -0.0348 | 0.00 | 0.021 | 0.00 | -- | -- | 0.00 | -88.55 | -25.19 | -100.85 | -27.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.05 | -- | -- | -- |
| ValiRx Plc | 9.60k | -1.97m | 2.02m | 8.00 | -- | 0.5245 | -- | 210.24 | -0.0172 | -0.0172 | 0.00008 | 0.0291 | 0.0025 | -- | 0.0639 | -- | -53.19 | -50.57 | -51.14 | -54.77 | 85.00 | -- | -21,512.29 | -103,908.50 | 6.27 | -- | 0.0048 | -- | -- | -- | 13.89 | -- | -1.13 | -- |
| TheraCryf PLC | 396.00k | -3.14m | 2.46m | 9.00 | -- | 0.6752 | -- | 6.21 | -0.0114 | -0.0114 | 0.0014 | 0.0085 | 0.0858 | -- | 0.9766 | 44,000.00 | -67.93 | -42.50 | -81.69 | -46.66 | -- | -- | -792.17 | -1,482.46 | -- | -- | 0.00 | -- | -10.41 | -- | 22.41 | -- | -- | -- |
| N4 Pharma PLC | 5.86k | -1.12m | 2.47m | 5.00 | -- | 1.97 | -- | 421.05 | -0.0042 | -0.0042 | 0.00002 | 0.0032 | 0.0041 | -- | 0.0421 | 1,172.00 | -79.19 | -57.05 | -83.28 | -61.13 | -- | -- | -19,152.56 | -309,312.80 | -- | -3,023.17 | 0.00 | -- | -- | -51.52 | -24.05 | -- | -- | -- |
| Fusion Antibodies PLC | 1.14m | -2.23m | 3.98m | 31.00 | -- | 2.21 | -- | 3.51 | -0.0426 | -0.0426 | 0.0205 | 0.0188 | 0.5069 | 2.36 | 2.02 | 36,645.16 | -99.33 | -41.50 | -147.47 | -52.23 | -3.96 | 40.19 | -195.95 | -56.92 | 3.09 | -1,144.00 | 0.0234 | -- | -60.84 | -12.24 | 14.25 | -- | -72.95 | -- |
| Genflow Biosciences PLC | 0.00 | -1.53m | 6.29m | 5.00 | -- | 7.33 | -- | -- | -0.0051 | -0.0051 | 0.00 | 0.0025 | 0.00 | -- | -- | 0.00 | -93.85 | -- | -118.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.97 | -- | -- | -- |
| ImmuPharma PLC | -69.96k | -2.46m | 6.91m | 5.00 | -- | 2.57 | -- | -- | -0.0065 | -0.0065 | -0.0002 | 0.0065 | -0.019 | -- | -- | -13,992.00 | -66.99 | -86.13 | -111.20 | -106.39 | -- | -- | -- | -8,634.98 | -- | -7.27 | 0.00 | -- | -- | -- | 23.26 | -- | -- | -- |
| LungLife AI Inc | 22.44k | -3.46m | 7.24m | 15.00 | -- | 0.3546 | -- | 322.62 | -0.1299 | -0.1299 | 0.0008 | 0.2409 | 0.0027 | -- | 2.90 | 1,496.27 | -42.18 | -- | -47.78 | -- | 100.00 | -- | -15,403.45 | -- | -- | -- | 0.0259 | -- | 91.67 | -- | 28.83 | -- | -- | -- |
| Cizzle Biotechnology Holdings PLC | 0.00 | -2.70m | 7.53m | 67.00 | -- | 9.49 | -- | -- | -0.0073 | -0.0073 | 0.00 | 0.002 | 0.00 | -- | -- | -- | -146.70 | -144.15 | -157.81 | -167.75 | -- | -- | -- | -- | -- | -0.45 | 0.00 | -- | -- | -- | -88.27 | -- | -- | -- |
| IXICO PLC | 6.00m | -1.87m | 7.99m | 89.00 | -- | 0.4155 | -- | 1.33 | -0.0386 | -0.0386 | 0.1241 | 0.2076 | 0.4725 | -- | 3.54 | 67,415.73 | -14.69 | 4.35 | -16.58 | 5.33 | 46.90 | 62.09 | -31.10 | 6.61 | -- | -- | 0.0312 | 0.00 | -22.89 | 4.32 | -214.15 | -- | 92.12 | -- |
| Synairgen plc | 0.00 | -6.92m | 9.26m | 36.00 | -- | 0.9624 | -- | -- | -0.0344 | -0.0344 | 0.00 | 0.0475 | 0.00 | -- | -- | 0.00 | -47.18 | -54.01 | -54.24 | -60.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.35 | -- | -26.64 | -- |
| OptiBiotix Health PLC | 569.00k | -2.98m | 12.24m | 5.00 | -- | 1.66 | -- | 21.52 | -0.0317 | -0.0317 | 0.0061 | 0.0752 | 0.0634 | 1.35 | 1.07 | 113,800.00 | -33.25 | 16.82 | -34.85 | 17.52 | 47.98 | 53.03 | -524.43 | 183.49 | 5.36 | -2.03 | 0.00 | 100.14 | 40.92 | 4.60 | -178.82 | -- | -- | -- |
| Hemogenyx Pharmaceuticals PLC | 0.00 | -5.18m | 16.97m | 17.00 | -- | 5.54 | -- | -- | -0.0042 | -0.0042 | 0.00 | 0.0023 | 0.00 | -- | -- | 0.00 | -77.79 | -82.19 | -85.95 | -95.97 | -- | -- | -- | -- | -- | -19.94 | 0.4794 | -- | -- | -- | -68.14 | -- | 36.68 | -- |
Data as of Nov 11 2024. Currency figures normalised to ImmuPharma PLC's reporting currency: UK Pound GBX
31.56%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| KW Investment Management Ltd.as of 02 Sep 2024 | 46.36m | 11.13% |
| Hargreaves Lansdown Asset Management Ltd.as of 02 Sep 2024 | 22.89m | 5.50% |
| Chelverton Asset Management Ltd.as of 31 Dec 2023 | 22.50m | 5.40% |
| HSBC Global Asset Management (UK) Ltd.as of 02 Sep 2024 | 13.26m | 3.18% |
| IG Markets Ltd.as of 02 Sep 2024 | 12.04m | 2.89% |
| iDealing.com Ltd.as of 02 Sep 2024 | 4.27m | 1.03% |
| Bank J. Safra Sarasin AG (Investment Management)as of 02 Sep 2024 | 3.25m | 0.78% |
| HSBC Bank Plc (Market-Maker)as of 02 Sep 2024 | 2.56m | 0.62% |
| Close Asset Management Ltd.as of 02 Sep 2024 | 2.21m | 0.53% |
| Aviva Investors Global Services Ltd.as of 20 Apr 2018 | 2.09m | 0.50% |
More ▼
Data from 30 Jun 2024 - 01 Nov 2024Source: FactSet Research Systems Inc.
